ATRECA
Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.
ATRECA
Social Links:
Industry:
Biotechnology Health Care Product Research Therapeutics
Founded:
2010-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.atreca.com
Total Employee:
51+
Status:
Active
Contact:
6505952618
Email Addresses:
[email protected]
Total Funding:
347.86 M USD
Technology used in webpage:
Google Maps IPv6 ReCAPTCHA ReCAPTCHA V2 Akamai Hosted Energy Group Hosting
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Founder
Stock Details
Investors List
Wellington Management
Wellington Management investment in Series C - Atreca
Samsara BioCapital
Samsara BioCapital investment in Series C - Atreca
Tavistock Life Sciences
Tavistock Life Sciences investment in Series C - Atreca
Redmile Group
Redmile Group investment in Series C - Atreca
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Atreca
Boxer Capital
Boxer Capital investment in Series C - Atreca
Aisling Capital
Aisling Capital investment in Series C - Atreca
EcoR1 Capital
EcoR1 Capital investment in Series C - Atreca
Tekla Capital Management
Tekla Capital Management investment in Series C - Atreca
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Atreca
Key Employee Changes
| Date | New article |
|---|---|
| 2023-01-09 | Atreca Appoints Philippe Bishop, MD as Chief Medical Officer |
| 2022-06-16 | Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer |
Official Site Inspections
http://www.atreca.com Semrush global rank: 3.9 M Semrush visits lastest month: 2.91 K
- Host name: 23.163.196.104.bc.googleusercontent.com
- IP address: 104.196.163.23
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Atreca"
Atreca - Crunchbase Company Profile & Funding
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. View contacts for Atreca to access new leads and connect with decision-makers.See details»
Atreca, Inc. - LinkedIn
Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer …See details»
Atreca, Inc. - AnnualReports.com
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform.See details»
Atreca Company Profile - Office Locations, Competitors, Revenue …
Jun 14, 2024 Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer …See details»
Atreca Announces Asset Purchase Agreement for Sale of Antibody …
Dec 26, 2023 Atreca, Inc. CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel …See details»
Atreca - BIO International Convention | BIO
Jun 5, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Atreca’s …See details»
Atreca - Contacts, Employees, Board Members, Advisors & Alumni
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. ... Products. Resources. Pricing. Resources. …See details»
Atreca Announces Corporate Reorganization to Extend Cash Runway
Jun 1, 2022 Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets Extends cash runway through 2023 and reduces workforce by more than 25% On track …See details»
Atreca - Bill & Melinda Gates Foundation
Atreca’s proprietary discovery platform generates and develops therapeutics based on rapid characterization of human adaptive immune response at the single cell level. Foundation …See details»
Atreca Enters into Licensing Agreement with Bill & Melinda Gates ...
SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics …See details»
Biotech company Atreca is winding down, but its antimalarial drug …
Jan 29, 2024 For Atreca to find a malaria-focused antibody, it had to score highly on World Health Organization guidelines for ease of manufacturing, a low cost of goods and viscosity — …See details»
Atreca, Inc., Completes Oversubscribed $56 Million ... - Fierce Biotech
Nov 5, 2015 Dr. William Robinson, Atreca Co-Founder and Board member, commented, "Atreca's technology has the potential to create a broad proprietary position within the immuno …See details»
Atreca Reports Third Quarter 2023 Financial Results and ... - Nasdaq
Nov 14, 2023 About Atreca, Inc. Atreca is a biopharmaceutical company developing novel antibody-based therapeutics generated by its differentiated discovery platform, with a focus on …See details»
Atreca downsizes again to focus on antibody-drug conjugate …
Nov 15, 2023 Atreca expects to file an investigational new drug (IND) application with the US Food and Drug Administration (FDA) in late 2024 or early 2025, as per a 10 August press …See details»
Atreca Announces Corporate Reorganization to Extend Cash …
SAN CARLOS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics …See details»
Atreca Announces Strategic Research Collaboration with
May 2, 2020 Under the terms of the agreement, Atreca will receive an upfront cash payment and retain exclusive ownership and rights to develop all Atreca antibodies included in the …See details»
Atreca Announces Expansion of Preclinical Pipeline - GlobeNewswire
Apr 5, 2022 Atreca Announces Licensing Agreement with Zymeworks. Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate. Virtual R&D Day scheduled for today at …See details»
Atreca Reports Third Quarter 2021 Financial Results and Recent ...
Nov 2, 2021 Atreca announced a licensing agreement with the Bill & Melinda Gates Medical Research Institute (“Gates MRI”) for development and commercialization of MAM01/ATRC …See details»
Atreca Is A Unique Biotech With Key Data Readouts In Coming Years
Nov 12, 2021 Atreca Inc. is a good speculative biotech to look into. It reported some good initial data with ATRC-101 being able to help 8 out of 20 advanced solid tumor patients achieve …See details»
Atreca (BCEL) Locks In A Catalyst In The Oncology Space
Feb 1, 2023 Atreca is a biotechnology company with a upcoming catalyst from its lead pipeline candidate, ATRC-101, in advanced solid malignancies.This article takes a look at the data to …See details»